An Advanced Digital Phenotype System Among People Suffering From Post-traumatic Stress Disorder

Nadav Goldental

Status: Unknown

Conditions: Post-traumatic Stress Disorder

Treatments: Device: BioBeat

Study type: Observational

Funder types: Other

Identifiers

NCT03788278

SHEBA-5184-18-SMC

Details and patient eligibility

About

Psychiatric diagnosis is based mainly on questioning the patient and subjective impression rather than a quantitative assessment. The assessment is usually done with long time intervals between assessments and arbitrary in relation to the clinical course of the disorder. Post-traumatic stress disorder has physiological, physical, and behavioral manifestations. These changes appear as a response to different situations during the day and can be measured directly and indirectly in order to obtain an objective, quantitative and fuller picture of the severity and changes in the disorder. This is a non-interventional pilot study, using a system that collects data through wearable sensors and smartphone over a long period of time for patients suffering from PTSD and enables data analysis and characterization of a personal digital phenotype using a dedicated algorithm. Based on this pattern, the investigators will attempt to support the establishment of the PTSD diagnosis. During the course of the study, the therapeutic procedure will not be affected by the study and will be independent of the research.

Enrollment: 50 estimated patients

Sex: All

Ages: 18 to 120 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria for study group:

• Current PTSD diagnosis based on DSM-5. We will aim to recruit patients with Clinically Administered PTSD Scale (CAPS)- 5, medium severity and up.
• A person who is being monitored by the Ministry of Defense PTSD clinic at the Sheba Medical Center.
• Proper ability to give informed consent.
• A person with a smartphone that is not hacked with an Android version 2.3 or higher (relevant to smartphones manufactured since 2011).

Inclusion Criteria for control group:

• Proper ability to give informed consent.
• A person with a smartphone that is not hacked with an Android version 2.3 or higher (relevant to smartphones manufactured since 2011).

Exclusion Criteria for study group:

• A person defined as a violent or suicidal person (significant events of physical violence or suicidal behavior in the past year, according to the treating psychiatrist professional opinion).
• An active or terminal oncology disease or a dialysis patient.
• A person who is not independent or reports that he/she will not meet the requirement to wear the watch, recharge it or any other requirement arising from the use of the watch.
• A person without a smartphone that is not hacked or without Android version 2.3 or higher (relevant to smartphones manufactured since 2011).

Exclusion Criteria for control group:

• Current mental health diagnosis.
• A person defined as a violent or suicidal person (significant events of physical violence or suicidal behavior in the past year, according to the treating psychiatrist professional opinion).
• An active or terminal oncology disease or a dialysis patient.
• A person who is not independent or reports that he/she will not meet the requirement to wear the watch, recharge it or any other requirement arising from the use of the watch.
• A person without a smartphone that is not hacked or without Android version 2.3 or higher (relevant to smartphones manufactured since 2011).

Trial design

50 participants in 2 patient groups

PTSD patients

Description:

Participants will attend clinical surveillance once every week or two. During the follow-up period, the participant will be checked as usual and will have to fill in questionnaires. Participants will be required to wear the smart watch at all times and will need to recharge it at least once every three days. Participants will be required to answer digital questionnaires twice a day via smartphone.

Treatment:

Device: BioBeat

Non PTSD participants

Description:

Participants will attend clinical surveillance once every week or two. During the follow-up period, the participant will be checked as usual and will have to fill in questionnaires. Participants will be required to wear the smart watch at all times and will need to recharge it at least once every three days. Participants will be required to answer digital questionnaires twice a day via smartphone.

Treatment:

Device: BioBeat